マーケットレポート詳細
CRISPRゲノム編集：世界市場2027年予測
CRISPR Technology: Global Markets
- 出版元：BCC Research
出版元について - 発行年：2023年1月
- 定価 ：Single User License $5,500 2-5 Users License $6,600 Site License $7,920 Enterprise License $9,504
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文131ページになります。
- 商品コード：BCC446
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
CRISPRゲノム編集の世界市場規模は、2022年の33億ドルから今後2027年には92億ドルへと拡大が予測されます。2022年から2027年にかけての同市場規模の平均年成長率は22.3%とレポートは分析しています。
当レポートでは、CRISPRゲノム編集の市場概要、各種セグメント別市場分析(エンドユーザー別、用途別、国地域別)、ファイブフォース分析、特許分析、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
◆イントロダクション
・調査目的
・調査対象
・調査手法
◆サマリーと調査ハイライト
◆市場概要
・CRISPR：ゲノム編集
・CRISPR-Casシステムの構造
・CRISPR-Casの仕組み
・CRISPR-Cas9システムの利点
・CRISPRゲノム編集の評判
・ゲノム編集の長所
・CRISPRの開発工程
・市場の可能性
・規制の枠組み
・CRISPR技術市場におけるファイブフォース分析
・科学出版物
・特許分析
・CRISPRの今後
・市場ドライバー
・市場障壁
・市場課題
◆産業構造
・商用化治療
・遺伝子欠陥の修正
・微生物
・健康食品
◆CRISPR技術市場へのCOVID-19の影響
・概要
◆競合状況
・概要
・競合シナリオ
・ビーム・セラピューティクス（Beam Therapeutics）
・CRISPRセラピューティクス（CRISPR Therapeutics）
・エディタス・メディシン（Editas Medicine）
・インテリア・セラピューティクス（Intellia Therapeutics）
・成長戦略
◆CRISPRゲノム編集市場：エンドユーザー別
・バイオテクノロジー/製薬企業
・学術研究機関/政府研究機関
・受託研究機関
※市場予測データ掲載-2027年
◆CRISPRゲノム編集市場：用途別
医薬品開発
農業
診断
・感染症
・非感染症
臨床療法
その他
※市場予測データ掲載-2027年
◆CRISPRゲノム編集市場：地域別
北米
欧州
・ドイツ、英国、フランス
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※地域別に主要国別の細分化データ掲載
※地域別に全セグメント別の細分化データ掲載、詳細は目次参照
◆CRISPRゲノム編集の主要企業プロフィール
・CARIBOU BIOSCIENCES
・CRISPR THERAPEUTICS AG
・DANAHER CORP.
・EDITAS MEDICINE
・GENSCRIPT
・HERA BIOLABS
・INTELLIA THERAPEUTICS INC.
・LONZA GROUP LTD.
・MAMMOTH BIOSCIENCES INC.
・NEW ENGLAND BIOLABS INC.
・ORIGENE TECHNOLOGIES
・PERKINELMER
・PRECISION BIOSCIENCES
・SYNTHEGO
・THERMO FISHER SCIENTIFIC
・TOOLGEN INC.
（全226頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
CHAPTER 1 INTRODUCTION
1.1 STUDY GOALS AND OBJECTIVES
1.2 REASONS FOR DOING THIS STUDY
1.3 INTENDED AUDIENCE
1.4 SCOPE OF REPORT
1.5 WHAT'S NEW IN THIS REPORT?
1.6 INFORMATION SOURCES
1.7 METHODOLOGY
1.8 GEOGRAPHIC BREAKDOWN
1.9 ANALYST'S CREDENTIALS
1.10 BCC CUSTOM RESEARCH
1.11 RELATED BCC RESEARCH REPORTS
CHAPTER 2 SUMMARY AND HIGHLIGHTS
2.1 HIGHLIGHTS OF THE MARKET FOR CRISPR TECHNOLOGY
CHAPTER 3 MARKET OVERVIEW
3.1 CRISPR: GENETIC EDITING
3.2 COMPONENTS OF CRISPR-CAS SYSTEMS
- 3.2.1 SGRNA
- 3.2.2 CAS9 NUCLEASES
3.3 HOW CRISPR-CAS WORKS?
3.4 ADVANTAGE OF THE CRISPR-CAS9 SYSTEM
3.5 POPULARITY OF CRISPR GENOME EDITING
3.6 PROS OF GENETIC EDITING
3.7 CRISPR DEVELOPMENT PHASES
- 3.7.1 DISCOVERY OF CRISPR
- 3.7.2 DISCOVERY OF CAS9 AND PAM
- 3.7.3 HYPOTHESIS: ADAPTIVE IMMUNITY
- 3.7.4 ADAPTIVE IMMUNITY
- 3.7.5 SPACER SEQUENCES: GRNAS
- 3.7.6 CRISPR ACTS ON DNA TARGETS
- 3.7.7 CAS9 CLEAVES TARGET DNA
- 3.7.8 TRACRRNA FOR CAS9 SYSTEMS
- 3.7.9 CRISPR SYSTEMS IN OTHER SPECIES
- 3.7.10 CAS9-MEDIATED CLEAVAGE
- 3.7.11 CRISPR-CAS9: GENOME EDITING
3.8 MARKET POTENTIAL
3.9 REGULATORY FRAMEWORK
- 3.9.1 U.S. REGULATION AND OVERSIGHT
- 3.9.2 NIH GUIDELINES
- 3.9.3 U.S. FDA
- 3.9.4 REGULATORY ISSUES
- 3.9.5 REGULATIONS OF HUMAN GERMLINE EDITS
- 3.9.6 GLOBAL REGULATIONS
3.10 PORTER'S FIVE FORCES ANALYSIS OF THE MARKET FOR CRISPR TECHNOLOGY
- 3.10.1 BARGAINING POWER OF SUPPLIERS: LOW
- 3.10.2 BARGAINING POWER OF BUYERS: MODERATE
- 3.10.3 THE THREAT OF SUBSTITUTES: MODERATE
- 3.10.4 THE THREAT OF NEW ENTRANTS: MODERATE
- 3.10.5 THE INTENSITY OF COMPETITIVE RIVALRY: LOW
3.11 SCIENTIFIC PUBLICATIONS
3.12 PATENT ANALYSIS
- 3.12.1 OVERVIEW OF CRISPR TECHNOLOGY INTELLECTUAL PROPERTY (IP) AND LICENSING STRUCTURE
3.13 FUTURE OF CRISPR
3.14 MARKET DRIVERS
- 3.14.1 CRISPR VERSUS CHRONIC DISEASE
- 3.14.2 HIGH PREVALENCE OF GENETIC DISORDERS
- 3.14.3 GOVERNMENT AND PRIVATE FUNDING
- 3.14.4 INCREASING APPLICATIONS OF CRISPR
3.15 MARKET RESTRAINTS
- 3.15.1 ALTERNATIVE TECHNOLOGIES
- 3.15.2 OFF-TARGET ACTIVITY
3.16 MARKET CHALLENGES
- 3.16.1 PATENT ISSUES
- 3.16.2 RISKS ASSOCIATED WITH CRISPR
- 3.16.3 R&D
- 3.16.4 GOVERNMENTAL POLICIES AND REGULATIONS
- 3.16.5 BIOETHICAL ISSUES
CHAPTER 4 INDUSTRY STRUCTURE
4.1 COMMERCIAL THERAPEUTICS
4.2 CORRECTING GENETIC ERRORS
4.3 MICROBES
4.4 HEALTHIER FOOD
CHAPTER 5 IMPACT OF COVID-19 ON THE MARKET FOR CRISPR TECHNOLOGY
5.1 OVERVIEW
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 OVERVIEW
6.2 COMPETITIVE SCENARIO
6.3 BEAM THERAPEUTICS
6.4 CRISPR THERAPEUTICS
6.5 EDITAS MEDICINE
6.6 INTELLIA THERAPEUTICS
6.7 GROWTH STRATEGIES
- 6.7.1 LICENSING AND AGREEMENTS
- 6.7.2 COLLABORATIONS WITH BIG BIOPHARMACEUTICAL COMPANIES
- 6.7.3 MERGERS AND ACQUISITIONS
CHAPTER 7 GLOBAL MARKET FOR CRISPR TECHNOLOGY BY END USER
7.1 MARKET OVERVIEW
7.2 MARKET SHARE AND FORECAST
7.3 BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
7.4 ACADEMICS AND GOVERNMENT RESEARCH INSTITUTES
7.5 CONTRACT RESEARCH ORGANIZATIONS
CHAPTER 8 GLOBAL MARKET FOR CRISPR TECHNOLOGY BY APPLICATION
8.1 MARKET SHARE AND FORECAST
8.2 DRUG DEVELOPMENT
8.3 AGRICULTURE
8.4 DIAGNOSTICS
- 8.4.1 INFECTIOUS DISEASES
- 8.4.2 NON-INFECTIOUS DISEASES
8.5 CLINICAL THERAPY
8.6 OTHERS
CHAPTER 9 GLOBAL MARKET FOR CRISPR TECHNOLOGY BY REGION
9.1 NORTH AMERICA
- 9.1.1 U.S.
- 9.1.2 CANADA
9.2 EUROPE
- 9.2.1 GERMANY
- 9.2.2 UNITED KINGDOM
- 9.2.3 FRANCE
- 9.2.4 REST OF EUROPE
9.3 ASIA-PACIFIC
- 9.3.1 CHINA
- 9.3.2 JAPAN
- 9.3.3 INDIA
- 9.3.4 REST OF ASIA-PACIFIC
9.4 REST OF THE WORLD
CHAPTER 10 COMPANY PROFILES
CARIBOU BIOSCIENCES
CRISPR THERAPEUTICS AG
DANAHER CORP.
EDITAS MEDICINE
GENSCRIPT
HERA BIOLABS
INTELLIA THERAPEUTICS INC.
LONZA GROUP LTD.
MAMMOTH BIOSCIENCES INC.
NEW ENGLAND BIOLABS INC.
ORIGENE TECHNOLOGIES
PERKINELMER
PRECISION BIOSCIENCES
SYNTHEGO
THERMO FISHER SCIENTIFIC
TOOLGEN INC.
LIST OF TABLES
SUMMARY TABLE B : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
SUMMARY TABLE A : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY END USER, THROUGH 2027
TABLE 1 : COMPARISON OF GENOME EDITING TECHNOLOGIES
TABLE 2 : SELECTED MONOGENIC DISEASE DETAILS
TABLE 3 : CRISPR APPLICATIONS
TABLE 4 : GLOBAL INCIDENCE OF CANCER, BY CANCER TYPE/SITE, 2020
TABLE 5 : VENTURE CAPITALIST FUNDING, BY COMPANY IN GENE EDITING
TABLE 6 : BIOETHICAL ISSUES AND RISKS ASSOCIATED WITH CRISPR TECHNOLOGY
TABLE 7 : SELECTED CAR-T/GENE-EDITING COLLABORATIONS
TABLE 8 : CRISPR TECHNOLOGY: COMPETITIVE SCENARIO
TABLE 9 : CRISPR TECHNOLOGY: SELECTED COMPANIES
TABLE 10 : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY END USER, THROUGH 2027
TABLE 11 : COLLABORATIONS AMONG BIOTECHNOLOGY AND PHARMACEUTICAL CRISPR TECHNOLOGY COMPANIES
TABLE 12 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN BIOTECHNOLOGY AND PHARMACEUTICAL END USES, BY REGION, THROUGH 2027
TABLE 13 : COMPANIES LICENSING CRISPR TECHNOLOGY FROM RESEARCH INSTITUTIONS
TABLE 14 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN ACADEMIC AND GOVERNMENT RESEARCH INSTITUTE END USES, BY REGION, THROUGH 2027
TABLE 15 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN CONTRACT RESEARCH ORGANIZATION END USES, BY REGION, THROUGH 2027
TABLE 16 : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY APPLICATION, THROUGH 2027
TABLE 17 : GLOBAL MARKET FOR DRUG DEVELOPMENT APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 18 : CRISPR: EDITED CROPS
TABLE 19 : GLOBAL MARKET FOR AGRICULTURE-BASED APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 20 : GLOBAL MARKET FOR DIAGNOSTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 21 : CLINICAL TRIAL USING CRISPR TECHNOLOGY FOR CHRONIC DISEASE
TABLE 22 : GLOBAL MARKET FOR CLINICAL THERAPEUTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 23 : GLOBAL MARKET FOR OTHER APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 24 : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY REGION, THROUGH 2027
TABLE 25 : EUROPEAN MARKET FOR CRISPR TECHNOLOGY, BY COUNTRY, THROUGH 2027
TABLE 26 : ASIA-PACIFIC MARKET FOR CRISPR TECHNOLOGY, BY COUNTRY, THROUGH 2027
TABLE 27 : CARIBOU BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 28 : CARIBOU BIOSCIENCES: RECENT DEVELOPMENTS, 2021
TABLE 29 : CRISPR THERAPEUTICS AG: PRODUCT PORTFOLIO
TABLE 30 : CRISPR THERAPEUTICS AG: RECENT DEVELOPMENTS, 2021 AND 2022
TABLE 31 : DANAHER: PRODUCT PORTFOLIO
TABLE 32 : DANAHER: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 33 : EDITAS MEDICINE: PRODUCT PORTFOLIO
TABLE 34 : EDITAS MEDICINE: RECENT DEVELOPMENTS, 2020-2022
TABLE 35 : GENSCRIPT: PRODUCT PORTFOLIO
TABLE 36 : GENSCRIPT: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 37 : HERA BIOLABS: PRODUCT PORTFOLIO
TABLE 38 : HERA BIOLABS: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 39 : INTELLIA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 40 : INTELLIA THERAPEUTICS INC.: RECENT DEVELOPMENTS, 2020-2022
TABLE 41 : LONZA GROUP LTD.: PRODUCT PORTFOLIO
TABLE 42 : LONZA GROUP LTD.: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 43 : MAMMOTH BIOSCIENCES INC.: RECENT DEVELOPMENTS, 2020-2022
TABLE 44 : NEW ENGLAND BIOLABS INC.: PRODUCT PORTFOLIO
TABLE 45 : NEW ENGLAND BIOLABS INC.: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 46 : ORIGENE TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 47 : PERKINELMER: PRODUCT PORTFOLIO
TABLE 48 : PERKINELMER: RECENT DEVELOPMENTS, 2020 AND 2021
TABLE 49 : PRECISION BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 50 : PRECISION BIOSCIENCES: RECENT DEVELOPMENTS, 2020-2022
TABLE 51 : THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 52 : THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS, 2020-2022
LIST OF FIGURES
SUMMARY FIGURE A : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY END USER, 2019-2027
SUMMARY FIGURE B : GLOBAL MARKET FOR CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 1 : CRISPR TIMELINE, 2016-2021
FIGURE 2 : DISTRIBUTION SHARES OF SCIENTIFIC PUBLICATIONS ON GENOME EDITING, BY TECHNOLOGY, 2018-2021
FIGURE 3 : DISTRIBUTION OF SCIENTIFIC PUBLICATIONS ON GENOME EDITING, BY YEAR, 2018-2021
FIGURE 4 : PUBLISHED PATENTS ON CRISPR TECHNOLOGY, 2011-2021
FIGURE 5 : PATENT FILINGS ON CRISPR TECHNOLOGY, BY JURISDICTION, 2011-2021
FIGURE 6 : SHARE OF PATENT FILINGS ON CRISPR TECHNOLOGY, BY APPLICANT, 2011-2021
FIGURE 7 : GLOBAL MARKET SHARES OF CRISPR TECHNOLOGY, BY END USER, 2021
FIGURE 8 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN BIOTECHNOLOGY AND PHARMACEUTICAL END USES, BY REGION, 2019-2027
FIGURE 9 : GLOBAL MARKET SHARES OF CRISPR TECHNOLOGY IN BIOTECHNOLOGY AND PHARMACEUTICAL END USES, BY REGION, 2021
FIGURE 10 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN ACADEMIC AND GOVERNMENT RESEARCH INSTITUTE END USES, BY REGION, 2019-2027
FIGURE 11 : GLOBAL MARKET SHARES OF CRISPR TECHNOLOGY IN ACADEMIC AND GOVERNMENT RESEARCH INSTITUTE END USES, BY REGION, 2021
FIGURE 12 : GLOBAL MARKET FOR CRISPR TECHNOLOGY IN CONTRACT RESEARCH ORGANIZATION END USES, BY REGION, 2019-2027
FIGURE 13 : GLOBAL MARKET SHARES OF CRISPR TECHNOLOGY IN CONTRACT RESEARCH ORGANIZATION END USES, BY REGION, 2021
FIGURE 14 : GLOBAL MARKET SHARES OF CRISPR TECHNOLOGY, BY APPLICATION, 2021
FIGURE 15 : CRISPR TECHNOLOGY IN DRUG DEVELOPMENT
FIGURE 16 : CRISPR TECHNOLOGY USAGE IN DRUG DEVELOPMENT, BY PHASE (COMMERCIAL)
FIGURE 17 : CRISPR TECHNOLOGY USAGE IN DRUG DEVELOPMENT, BY PHASE (NON-COMMERCIAL)
FIGURE 18 : GLOBAL MARKET FOR DRUG DEVELOPMENT APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 19 : GLOBAL MARKET SHARES OF DRUG DEVELOPMENT APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2021
FIGURE 20 : GLOBAL MARKET FOR AGRICULTURE-BASED APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 21 : GLOBAL MARKET SHARES OF AGRICULTURE-BASED APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2021
FIGURE 22 : GLOBAL MARKET FOR DIAGNOSTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 23 : GLOBAL MARKET SHARES OF DIAGNOSTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2021
FIGURE 24 : GLOBAL MARKET FOR CLINICAL THERAPEUTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 25 : GLOBAL MARKET SHARES OF CLINICAL THERAPEUTIC APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2021
FIGURE 26 : GLOBAL MARKET FOR OTHER APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2019-2027
FIGURE 27 : GLOBAL MARKET SHARES OF OTHER APPLICATIONS OF CRISPR TECHNOLOGY, BY REGION, 2021
FIGURE 28 : SNAPSHOT OF THE GLOBAL MARKET FOR CRISPR TECHNOLOGY
FIGURE 29 : NORTH AMERICAN MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 30 : EUROPEAN MARKET SHARES OF CRISPR TECHNOLOGY, BY COUNTRY, 2021
FIGURE 31 : GERMAN MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 32 : U.K. MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 33 : FRENCH MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 34 : REST OF THE EUROPEAN MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 35 : ASIA-PACIFIC MARKET SHARES OF CRISPR TECHNOLOGY, BY COUNTRY, 2021
FIGURE 36 : CHINESE MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 37 : JAPANESE MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 38 : INDIAN MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 39 : REST OF ASIA-PACIFIC MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 40 : ROW MARKET FOR CRISPR TECHNOLOGY, 2019-2027
FIGURE 41 : CARIBOU BIOSCIENCES: ANNUAL REVENUE, 2019-2021
FIGURE 42 : CRISPR THERAPEUTICS AG: ANNUAL REVENUE, 2019-2021
FIGURE 43 : DANAHER: ANNUAL REVENUE, 2019-2021
FIGURE 44 : DANAHER: MARKET SHARE, BY REGION, 2021
FIGURE 45 : DANAHER: MARKET SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 46 : EDITAS MEDICINE: ANNUAL REVENUE, 2019-2021
FIGURE 47 : GENSCRIPT: ANNUAL REVENUE, 2019-2021
FIGURE 48 : GENSCRIPT: MARKET SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 49 : GENSCRIPT: MARKET SHARE, BY REGION, 2021
FIGURE 50 : INTELLIA THERAPEUTICS INC.: ANNUAL REVENUE, 2020 AND 2021
FIGURE 51 : LONZA GROUP LTD.: ANNUAL REVENUE, 2019-2021
FIGURE 52 : LONZA GROUP LTD.: MARKET SHARE, BY REGION, 2021
FIGURE 53 : LONZA GROUP LTD.: MARKET SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 54 : PERKINELMER: DISCOVERY AND ANALYTICAL SOLUTIONS, REVENUE, 2019-2021
FIGURE 55 : PERKINELMER: MARKET SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 56 : PERKINELMER: MARKET SHARE, DISCOVERY AND ANALYTICAL SOLUTIONS, BY REGION, 2021
FIGURE 57 : PRECISION BIOSCIENCES: ANNUAL REVENUE, 2019-2021
FIGURE 58 : PRECISION BIOSCIENCES: MARKET SHARE, BY BUSINESS SEGMENT, 2021
FIGURE 59 : THERMO FISHER SCIENTIFIC INC.: ANNUAL REVENUE, 2019-2021
FIGURE 60 : THERMO FISHER SCIENTIFIC INC.: MARKET SHARE, BY REGION, 2021
FIGURE 61 : THERMO FISHER SCIENTIFIC INC.: MARKET SHARE, BY BUSINESS SEGMENT, 2021